About AMILI
AMILI is a company based in Singapore (Singapore) founded in 2019 by David Ong, Jonathan Lee, Christopher Ting, Dennis von Berlepsch, and Jeremy Lim. AMILI has raised $10.5 million across 2 funding rounds from investors including Emtek, G. K. Goh Holdings and Pruksa. AMILI offers products and services including Gut Health Test Kits, Probiotics, Faecal Microbiota Transplant, and AMILI Analytics. AMILI operates in a competitive market with competitors including Wacker Chemie, Enduro, BioCina, BDI biotech and Vibalogics, among others.
- Headquarter Singapore, Singapore
- Founders David Ong, Jonathan Lee, Christopher Ting, Dennis von Berlepsch, Jeremy Lim
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$1.37 M (USD)72as on Apr 30, 2024
-
Net Profit
-$3.91 M (USD)15as on Apr 30, 2024
-
EBITDA
Not available
-
Total Equity Funding
$10.5 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
-
Investors
Emtek
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AMILI
AMILI offers a comprehensive portfolio of products and services, including Gut Health Test Kits, Probiotics, Faecal Microbiota Transplant, and AMILI Analytics.
Kits for testing gut microbiome to provide personalized health insights.
Supplements designed to enhance gut microbiome balance and functionality.
Service for transplanting microbiota to treat gut health issues effectively.
Platform for analyzing gut microbiome data for industry partners.
People of AMILI
Unlock access to complete
Unlock access to complete
Funding Insights of AMILI
AMILI has successfully raised a total of $10.5M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AMILI
AMILI has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Emtek, G. K. Goh Holdings and Pruksa.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in Southeast Asian startups and publishing reports on technology and sustainability.
|
Locked | Locked | Locked | |
|
Private equity investments are backed by a single-family office firm.
|
Locked | Locked | Locked | |
|
Capital is invested in life science innovations for healthcare transformation.
|
Locked | Locked | Locked |
Investor details for AMILI
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AMILI
Investment portfolio details for AMILI
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AMILI
Detailed financials for AMILI
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Amili Comparisons
Peer comparison for AMILI
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AMILI
AMILI operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Wacker Chemie, Enduro, BioCina, BDI biotech and Vibalogics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Silicones, polymers, and bio-solutions are manufactured for various industries.
|
|
| Locked | Locked | Locked |
Microbial strains are manufactured by Enduro as a CDMO.
|
|
| Locked | Locked | Locked |
CDMO offering microbial expression systems-based biologics development and manufacturing services
|
|
| Locked | Locked | Locked |
Microbial strains for biopharma are developed at BDI Biotech.
|
|
| Locked | Locked | Locked |
CDMO offering development, cGMP manufacturing and fill/finish of biologics based on viruses and bacteria
|
Detailed competitors of AMILI
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Amili
Complete news archive for AMILI
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AMILI
AMILI was founded in 2019 and raised its 1st funding round 3 years after it was founded.
AMILI is headquartered in Singapore, Singapore.
Jeremy Lim is the current CEO of AMILI. They have also founded this company.
AMILI is a funded company, having raised a total of $10.5M across 2 funding rounds to date.
Annual revenue of AMILI is $1.37M as on Apr 30, 2024.
AMILI was founded in 2019 in Singapore and operates within the gut health sector. Data insights and analytics on microbiome abundance, functionality, and health effects are delivered through a specialized platform. Microbiome-enabled products and services are formulated for industry partners, while proprietary test kits and probiotics are made available. Therapeutics and diagnostics focused on gut health are also developed.
AMILI's top competitors include Wacker Chemie, Enduro and BioCina.
AMILI offers Gut Health Test Kits, Probiotics, Faecal Microbiota Transplant, and AMILI Analytics.
AMILI has 10 investors. Key investors include Emtek, G. K. Goh Holdings, Pruksa, East Ventures, and Vulcan Capital.